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was administered to a sample ofmale university students aged 18-26 years. Patient
characteristics measured included education, race, major, marital/relationship
status and insurance status. Awareness regarding HPV and the vaccine, and atti-
tude towards willingness to get vaccinated, perceived risks of being infected with
HPV, and benefits of the vaccine weremeasured using a 5 point Likert scale. Coded
data were analyzed by conducting descriptive and correlation analysis using SAS
9.2. RESULTS: A total of 203 completed surveys were obtained. Mean (SD) age of
participants was 21.56 (2.44) years. Mean awareness scores were high for HPV
(3.89  1.34) and HPV vaccine (3.55  1.30). Mean attitude scores were somewhat
mixed for willingness to get vaccinated (2.89  1.10), benefit of vaccination (3.18 
1.04), and at risk of getting HPV (3.15 1.21). There was no significant co-relation-
ship between attitude and awareness variables. Willingness to get vaccinated was
negatively correlated with perceived risk (r0.15, p 0.05) and vaccination benefit
(r0.34, p0.05). CONCLUSIONS: Despite awareness regarding HPV and HPV vac-
cine a large proportion of the cohort was not willing to get vaccinated. This may be
due to the perception of not being at risk of getting infected and not having a clear
understanding of the benefits of vaccination.
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OBJECTIVES: Despite it=s importance, there are few published studies describing
the burden of pneumococcal disease in elderly population of developing countries.
The goal of this study is to estimate the burden of pneumococcal diseases inMexico
in people 50 years.METHODS: Mortality due to pneumonia, bacteremia, menin-
gitis and acute otitis media (AOM) in patients 50 years was extracted from Mex-
ican MoH official databases (2009 data, ICD-10 classification). Population structure
was extracted from the Mexican official source. Incidence and prevalence of pneu-
mococcal disease were extracted from published sources. Mortality was adjusted
according to the proportion of deaths attributable to pneumococcal disease (from
literature). Data were analyzed with DISMOD II software (to produce consistent
estimates for epidemiological parameters of pneumococcal disease). Presence and
type of comorbidities were taken in account: low risk: without comorbidities; mild
risk: congestive heart failure, valvular disease, valvular disorders, pulmonary hy-
pertension, peripheral vascular disease, hypertension, ischemic heart disease,
stroke, COPD, diabetes mellitus, chronic renal failure, chronic liver disease, use of
tobacco and alcohol abuse; high risk: comorbidities associated to HIV/AIDS, lym-
phoma, tumors, splenic disease and sickle cell anemia. RESULTS: For 2009 were
estimated 12,798 cases ofmeningitis, where 86% of patients had low risk and 13%had
moderate risk of comorbidity, mortality rate was 1.6 per 100,000 inhabitants. For out-
patient pneumonia 4,275 cases were estimated, 53% low risk and 46% mild risk. For
inpatient pneumonia 31,631 cases were estimated, 78% low risk and 21% mild risk,
mortality rate: 7.8 per 100,000. For AOM 9,817 cases were estimated (100% low risk).
Meanwhile, 611casesofbacteremiawereestimated, 98%had lowriskand2%hadmild
risk. CONCLUSIONS: The availability of reliable epidemiological parameters regard-
ingpneumococcal disease inMexicanpopulationover 50 could support theevaluation
of current prevention policies, as well as the design of more efficient ones.
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OBJECTIVES: Complicated skin and skin structure infections (cSSSI) are a common
reason for hospitalization. Inappropriate empiric therapy (IAET) for cSSSI prolongs
hospital stay. Patients with a mixed cSSSI (MSI, gram positives [GP] and gram
negatives [GM] present) are at an increased risk for receiving IAET. We set out to
examine the bacteriology and components of IAET coverage inMSI.METHODS:We
conducted a single-center retrospective cohort study of patients hospitalized April
2006 to December 2007 with a cSSSI. IAET was defined as failure to deliver an
antibiotic with in vitro activity against the offending pathogen(s) within 24 hours of
presentation. RESULTS: Of the 717 patients hospitalized with a cSSSI, 158 (22%)
received IAET; 68 (9.5%) had a MSI. Among all MSI, most frequently isolated patho-
gens were methicillin-resistant S. aureus (MRSA) (n23, 33.8%), Streptococcus sp.
(n22, 32.4%) and P. aeruginosa (n21, 30.9%). IAET was noted in 26 (38.2%) MSIs.
Both appropriate GP andGN coverageweremissing in 7 (26.9%) cases.While among
all MSIs treated with IAET Streptococcus sp. coverage was never missing, treatment
for MRSA was absent in 3 (11.5%) cases. Most frequently missing coverage was for
GN (n18, 69.2%), with P. aeruginosa untreated in 6 (23.1%). GP coverage was absent
in 15 (57.7%), most frequently for vancomycin-resistant Enterococcus sp. (VRE) (n9,
34.6%).CONCLUSIONS: In this single-center study, patientswith aMSIwere at high
risk for IAET. Coverage was more frequently left out for GN than for GP, with P.
aeruginosa and VRE frequently remaining untreated empirically.
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OBJECTIVES: In the absence of reminders, multi-dose vaccine completion rates for
adolescents and adults are low. Human papillomavirus (HPV) vaccine completion,
for example, is 32% among US adolescents. In the IMPACT trial (Improving Patient
Adherence through Clinic-initiated Text messages), we examine the efficacy of
automated text message-based reminders in improving series completion rates
among patients 9 years old who have begun, but not completed, one or more
multi-dose vaccine series: hepatitis B (HBV) or HPV.METHODS: In thismulti-center
randomized controlled trial, consenting participants (N334)were assigned during
a clinical visit to receive either 1) text message-based reminders before their next
dose, or 2) traditional appointment reminders. In group 1, text messages were
delivered to patients’ or parents’ cellular telephones using aweb-based application
that automatically sends text reminders prior to appointments dates entered by
clinical staff. We evaluated the association between treatment group and appoint-
ment attendance and vaccine series completion RESULTS: Among all participants,
HPV or HBV series completion within 6 months of enrollment was higher for those
receiving a text messages (39.8 % vs. 32.0%), but with meaningful effect modifica-
tion by age. Among adult patients, those who received a text were more likely to
complete their vaccine series for HPV or HBV (37.5% vs. 24.2%; risk ratio [RR] 1.55).
Among adult patients who initiated the HPV series alone, text messages doubled
the rate of vaccine completion (37.5% vs. 18.5%; RR 2.03). Textmessaging was not
effective for increasing series completion among adolescent participants. Text
messaging improved overall appointment attendance at 3 of the 4 clinical sites, but
the differenceswere not statistically significant.CONCLUSIONS: In this pilot study,
text messaging initiated by the clinical office demonstrated improved multi-dose
vaccine series completion among adult patients and showed promising trends for
reducing appointment no-show rates.
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OBJECTIVES: Research has consistently demonstrated the effectiveness of antiret-
roviral therapy (ART) in reducing HIV-related morbidity and mortality. Current
guidelines for the treatment of HIV identify specific combination regimens with
medications from two different drug classes. The objective of this study was to
assess compliance with these guidelines among treatment-naïve individuals.
METHODS: Mississippi Medicaid prescription claims data (1/2008 10/2011) were
analyzed for beneficiaries who met eligibility criteria: age 17, not pregnant, and
enrolled in Medicaid for at least three months prior to the index prescription date.
Beneficiaries were considered treatment-naïve and starting initial therapy if no
ART claims existed for at least threemonths prior to the first ART claim.Wedefined
a guideline-adherent ART regimen as use of a minimum of three drugs including
two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with one
protease inhibitor (PI) or one nonnucleoside reverse transcriptase inhibitor (NNRTI)
between July 2008 and December 2010. Between January 2010 and November 2011,
a guideline-adherent ART regimen could also include two NRTIs in combination
with one integrase inhibitor. RESULTS: A total of 604 beneficiaries met inclusion
criteria. Between July 2008 and December 2009, 39.8% and 25.5% of beneficiaries
were on an NNRTI-based regimen and PI-based regimen, respectively. Addition-
ally, 4.4%metmore than one guideline simultaneously. Approximately 30.3%were
prescribed a medication regimen that was not in accordance with guidelines. Be-
tween January 2010 and October 2011, 38.8% and 24.1% of beneficiaries were on an
NNRTI-based regimen and PI-based regimen, respectively. Additionally, 5.3% met
more than one guideline simultaneously. Approximately 25.5% were prescribed a
medication regimen that was not in accordance with guidelines. CONCLUSIONS:
During the study period, the majority of beneficiaries were in accordance with
treatment guidelines for initial therapy for treatment-naïve patients withminimal
temporal changes across the three primary combination regimens.
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OBJECTIVES: Streptococcus pneumoniae is responsible for more than a million
deaths globally each year, most of them in the developing world. The burden of S.
pneumoniae infections is highest in children. Estimates in adult population are un-
common. Our objective was to determine the burden of disease, measured in dis-
ability adjusted life years (DALYs), associated with pneumococcus in adults (older
than 15 years of age) in Colombia in 2008.METHODS: Using different data sources
(national mortality records, official registries, published literature and local epide-
miological data) we estimated incidence, mortality and disability due to bacterial
pneumonia, bacterial meningitis and bacteremia of any cause for year 2008, and
the fraction of these that can be attributed to S. pneumoniae. We used Murray’s
standard methodology to estimate DALYs (including age-weighting and discount-
ing at 3%). RESULTS: There were 6488, 1276 and 452 deaths due to pneumonia,
bacteremia andmeningitis, respectively. Incidence rates for these same 3 diseases
(before adjusting for underreporting, that has been estimated in 65%) were 233,814;
999 and 960, respectively. A total of 63,463 DALYs are lost due to S. pneumoniae in
Colombians age 15 or over (55,362DALYs, 87%, due to premature death).Most of the
burden (51,848 DALYs, 81.7%) is due to pneumonia, followed by meningitis (9,241
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DALYs, 14.6%). For the age group 65 and over, after adjusting for population, the
burden increases 7 fold. The 3 conditions, overall, represent 2,03 DALYs per 1000
Colombians in that age range. CONCLUSIONS: Despite the lower incidence of
pneumococcal disease in adults, as compared with children, its burden is still
significant, comparable, for example, to that of schizophrenia or epilepsy in Co-
lombia. This study may provide a benchmark for future preventive interventions
and for efficient resource allocation.
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OBJECTIVES: To review the changes in HIV in terms of course of the disease over
the past five years and its consequences, to assess whether existing economic
models in HIVwould need to be updated to account for these changes in case these
were used for the economic evaluation of new treatments in HIV. METHODS: A
systematic literature review was carried out in PubMed, using both MeSH and key
words, focusing on the following areas: opportunistic infections (OIs), health con-
sequences, costs, quality of life, adherence and compliance and efficacy of treat-
ments. In addition, current guidelines were identified and reviewed. For treat-
ments we focussed on maraviroc, etravirine and raltegravir. RESULTS: At total of
1787 hits were obtained from the above-mentioned strategy. Finally data on 341
articles extracted. For treatments, data from six trials on efficacy and adverse event
datawere extracted and used in ameta-analysis (not reported here). In terms of OIs
it was clear that fewer patients suffer from these infections compared to the early
2000s. Data on costs indicated that new costs were available by CD4 cell count.
There are substantial new data available on quality of life in HIV, however, with
several publications providing data by CD4-cell strata. Data on health conse-
quences showed that patients increasingly live long enough to suffer from LT
health consequences such as cardiovascular disease and cancer. Guidelines indi-
cated that treatment algorithms had changed markedly in the last five years and
that comparison to OBT is no longer an acceptable comparator strategy in eco-
nomic modelling. CONCLUSIONS: The management of HIV has changed substan-
tially since 2006. Patients live longer, are healthier and suffer from “common”
health consequences such a cardiovascular disease and cancer. Any health eco-
nomic model in this disease area should take these aspects into consideration.
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OBJECTIVES: When modeling the course of disease it is crucial to make proper
assumptions concerning transition probabilities between health states. Two dif-
ferent approaches may be adopted: constant or time-dependent probabilities (i.e.
survival curves). Most of published economic analyses of hepatitis C treatment are
based on models with constant probabilities. Using survival curves is more time-
consuming and complex butmay result inmore accurate estimates. Our aimwas to
compare the impact of both methods on results of chronic hepatitis C modeling.
METHODS: A Markov model was developed to describe hepatitis C patients flow.
Time horizon of 50 years was chosen, cycle length was 1 year. Health states distin-
guished in the model were: fibrosis, compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplant (LT) and death. The
possible transitions were: fibrosis-CC, CC-DC, CC-HCC, DC-HCC, DC-LT
and from each state to death. Transition probabilities between health states were
estimated based on clinical trials evaluating the natural course of chronic hepatitis
C progression: either by calculating constant yearly rates or by using Weibull
curves estimated from reported Kaplan-Meier curves (the same data source for
each transition). Time spent in each of health states was compared between those
two approaches. RESULTS:The average time spent by a CC patient in states CC, DC,
HCC and LT was 18.3, 1.6, 0.3 and 1.3 years for constant probabilities, and 14.2, 3.2,
1.1 and 1.6 years for survival curves. Average survival was 21.5 and 20.2 years,
respectively. CONCLUSIONS:Method of calculation of transition probabilities may
have a significant impact on results of modeling, which may further influence
incremental cost-effectiveness ratios in economic analyses. The decision on the
method should bemade on the base of nature of events that are beingmodeled – for
some it may be more accurate to apply the survival curves approach.
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OBJECTIVES: To illustrate the application of an extended Cox regression model
with time-dependent treatment effects to real-world observational data.
METHODS: A retrospective US hospital database analysis was conducted among
adult invasive aspergillosis (IA) patients receiving their first antifungal therapy
during ICU stay. To assess the initial antifungal treatment effect on survival/LOS, a
survival analysiswas conductedwith event defined as “discharged alive”, censored
being “expired in hospital”, and time variable being treatment-initiation-to-dis-
charge (DITD). Key demographic, clinical and treatment variables were included.
Regimen A was the reference group and compared to regimen B (inactive against
IA, possibly indicating a treatment delay). Proportional hazard assumptions for the
treatment variable were assessed by the Schoenfeld residuals significance test.
When significant, treatment-by-time interaction together with its main effects
were included within an extended Cox model to account for the proportional haz-
ard violation. Multiple functional forms for time were considered in treatment-by-
time interactions. Due to the lack of direct SAS output for specific time points,
time-specific hazard ratios (HR) between treatments were manually calculated
incorporating bothmain effects and time covariates.RESULTS:A continuous linear
treatment-by-time interaction was constructed for Drug B since the null hypothe-
sis of Schoenfeld test was rejected. Consistent with an increasing time-interaction
effect (HR1.032, p0.0001), HR of drug B increased over time: Drug B patientswere
57% less likely (HR0.43, p.0001) to be discharged alive compared to Drug A at
mean switch time to other IA-active drugs (9 days), and 27% less likely (HR0.73,
p0.0297) to be discharged alive at mean DITD (25 days). Hazards would be equiv-
alent (HR1) at day 35, although by then most patients on regimen A (81%) had
switched/been discharged. CONCLUSIONS: The extended Coxmodel can be imple-
mented as an adjustment for the proportional hazard violation in observational
data analysis to obtain unbiased survival results.
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OBJECTIVES: In retrospective claims-based studies of drug exposures and resultant
safety/tolerability issues (TIs), researchersmust define an a-priori “at-riskwindow”
– the time period in which observed TIs are classified as resulting from drug expo-
sure. In HIV, interruption of combination antiretroviral therapy (cART) may cause
detrimental clinical outcomes; thus, if a TI necessitates a switch in cART, the
claims-based evidence of healthcare utilization for TIs may persist even after
switching. This study quantified the impact of at-risk window assignment on ret-
rospectively-estimated incidence and costs of TIs.METHODS: Data were Medicaid
claims from 15 states. Subjects were HIV patients 18–64 years old initiating
atazanavir, darunavir, fosamprenavir, or lopinavir-based cART regimens from Jan-
uary 1, 2003 to July 1, 2010. Outcomes: incidence and costs of new-onsetmedically-
attended (ICD-9-CM-coded or treated) TIs (gastrointestinal, lipid abnormalities, di-
abetes/hyperglycemia, rash, jaundice) during a period of up-to 6 months post-
cART-initiation or censoring at switch. RESULTS: Sample included 20,024 patients;
mean age 42 years, 34% female, 48% black. When extending the at-risk window for
7 days post-switch, differences in incidence rates of TIs per 1,000 patient-months
were: gastrointestinal (76.1 with extension vs. 73.7 without); lipid abnormalities
(23.5 vs. 22.3); diabetes/hyperglycemia (9.0 vs. 8.8); rash (98.5 vs. 96.0); jaundice (0.59
vs. 0.57). When extending the cost-accrual window to include costs of TIs that
persist after switching, differences in the estimated per-patient per-month (PPPM)
costs of TIs were: gastrointestinal ($72 with extension vs. $75 without); lipid abnor-
malities ($27 vs. $22); diabetes/hyperglycemia ($71 vs. $67); rash ($7 vs. $8); jaundice
($0.4 vs. $2). CONCLUSIONS: Extension of at-risk windows increased estimated
incidence rates of TIs, decreased estimated PPPM costs of acute TIs (i.e., gastroin-
testinal, rash, jaundice) and increased the estimated PPPM cost of chronic TIs (i.e.,
lipid abnormalities, diabetes/hyperglycemia). These novel results may inform fu-
ture retrospective studies of TIs in cART.
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OBJECTIVES: Atopic dermatitis is a chronically relapsing inflammatory skin con-
dition accompanied by pruritus which, when severe, can negatively impact a pa-
tient’s quality of life. The objective of this study was to perform ameta-analysis of
randomized controlled trials (RCTs) of topical therapies compared against their
vehicles, and systemic therapies compared against their placebos, and to record
how these therapies changed the magnitude of pruritus associated with atopic
dermatitis. METHODS: Data for this meta-analysis were extracted from Medline,
Embase, and the Cochrane Controlled Clinical Trials Register, as well as follow-up
references in retrieved articles from years 1977 to 2011. Initial search of systemic
therapies in relieving the pruritus of atopic dermatitis yielded 205 studies. Out of
the 205 studies, 52 studiesmet the inclusion criteria, with 41 and 11 studies involv-
ing topical and systemic treatment of pruritus of atopic dermatitis, respectively.
Standard inverse variance fixed-effects meta-analysis was used to calculate the
pooled estimates for RCTs falling under each type of treatment. RESULTS: The 52
studies were analyzed using STATA SE version 10. Meta-analysis results showed
that overall, compared to systemic medication of atopic dermatitis, the topical
medications significantly reduced atopic pruritus by 35.3% (RR, 0.647; 95%CI, 0.619-
0.677). Among the topical medications, compared to the use of vehicle, the use of
anti-histamines, calcineurin inhibitors and topical corticosteroids as therapeutic
agents significantly reduced the pruritus of atopic dermatitis by 27%, 36% and 34%
in patients, respectively. CONCLUSIONS: The topical treatments were more suc-
cessful at reducing atopic pruritus compared to the systemic treatments. Overall,
calcineurin inhibitors were the most effective antipruritic agents. Verifiable pruri-
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